Noble Life Science Partners
Nathan Cali

Investors Overview

Symbol
Exchange
Price
Change (%)
AQS
TSX-V
$0.00
+0.02 (0%)
Data as of
Minimum 20 minute delay
Symbol
Exchange
Price
Change (%)
AQSZF
OTCQB
$0.00
+0.02 (0%)
Data as of
Minimum 20 minute delay

Aequus Pharmaceuticals Inc. (TSX-V: AQS) is a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ management team has a proven track record of managing drug development from product validation through commercial launch, including clinical development and regulatory approval processes as well as launching and marketing products both directly and with commercial partners.  

Commercial strategy Aequus has a pipeline of commercial and near-commercial products that have been brought in through an acquisition or license to be marketed in Canada. We will continue to expand our commercial pipeline with high quality, differentiated products including patented products, branded generics, and reformulated novel-delivery products within focused therapeutic areas. Aequus continues to evaluate and develop additional product candidates that the Company believes to have significant commercial potential through both internal research and development efforts and external collaborations.

Development strategy. Aequus is developing several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. These products combine new delivery technologies, such as transdermal patches, with currently approved medicines that are limited by their current route of delivery.

View Aequus’ Full Product Pipeline

Aequus depends on the compliance of its directors, officers, consultants, associates and employees of Aequus and each of its subsidiaries to conduct business in line with its Code of Conduct and Ethics. To review the Code of Conduct and Ethics, click here

Latest News

Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole

Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch

Aequus Provides Second Quarter 2017 Operational Highlights

See All News